Da	te:15th, July	,2022		
	ur Name:Xiaoling			
			gets for viral hepatic fibrosis, alcoholic hepatic fibrosis, ar	nd
no	n-alcoholic hepatic fibrosis			
Ma	anuscript number (if known)	:ATM-22-3593		
In rel pa to rel Th ma	the interest of transparency ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only. e author's relationships/act the epidemiology of hypertedication, even if that medicated the documents of the epidemiology of the dication, even if that medicated the tent of the epidemiology of the e	we ask you to disclose all manuscript. "Related" mea affected by the content on ecessarily indicate a bias. it is preferable that you do to the author's relationship ivities/interests should be ension, you should declare eation is not mentioned in the	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the manuscript. Disclosure represents a commitment of the manuscript about whether to list a so. ps/activities/interests as they relate to the current of the current of the current of antihypertensive the manuscript.	
	item #1 below, report all su e time frame for disclosure i	•	d in this manuscript without time limit. For all other item	ıs,
	· •	•	Specifications/Comments (e.g., if payments were made to you or to your institution)	ns,
	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	ns,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	ns,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	ns,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	ns,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initia _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ns,
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initia _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ns,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initia _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ns,
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initia _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ns,
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initia _X_None Time frame: past _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ns,
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initia _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ns,

4

Consulting fees

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Comment for a strong diagram	37 NI	
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary	_X_None	
	role in other board,		
	society, committee or		
	advocacy group, paid or unpaid		
11	Stock or stock options	_X_None	
11	Stock of Stock options	Aivolic	
12	Receipt of equipment,	X_None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
13	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	llowing box:
	None.		

Da	te:15th, July	,2022	
	ur Name:Ying Wang		
			gets for viral hepatic fibrosis, alcoholic hepatic fibrosis, an
no	n-alcoholic hepatic fibrosis _.		
Ma	anuscript number (if known)):ATM-22-3593	
rel pa to rel Th ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, ationship questions apply inuscript only. e author's relationships/act	manuscript. "Related" means affected by the content of the author's relationship in the content of the content	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	item #1 below, report all su e time frame for disclosure i	• • • • • • • • • • • • • • • • • • • •	d in this manuscript without time limit. For all other item
	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initiaX_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initiaX_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work

_X__None

4

Consulting fees

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	_X_None	
0	pending	ANone	
	penunig		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary	_X_None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
	None.		
1			

Da	te:15th, July	,,2022		
Yo	ur Name:Xuewei Li			
			gets for viral hepatic fibrosis, alcoholic hepatic fibrosis, a	and
no	n-alcoholic hepatic fibrosis _.			
Ma	nuscript number (if known):ATM-22-3593		
related to the t	ated to the content of your rties whose interests may b transparency and does not ationship/activity/interest, e following questions apply muscript only. e author's relationships/act the epidemiology of hypert edication, even if that medication.	manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do to the author's relationship ivities/interests should be ension, you should declare cation is not mentioned in t	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.	
ln i	e time frame for disclosure i	• •	d in this manuscript without time limit. For all other iter	ms,
ln i	· · · · · · · · · · · · · · · · · · ·	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
ln i	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
In i	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
ln i	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
In i	All support for the present manuscript (e.g., funding, provision of study	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
In i	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
In i	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
In i	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
In i	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
In i	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ms,
In i the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initia _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ms,
In i	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ms,
In i the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initia _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ms,
In i the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initia _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work	ms,

Consulting fees

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	_X_None	
0	pending	ANone	
	penunig		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary	_X_None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
	None.		
1			

Dat	te:15th	, July,2022			
	ur Name:Shu				
			erapeutic ta	rgets for viral hepatic fibrosis, alcoholic hepatic fibrosi	s, and
noı	n-alcoholic hepatic fibr	osis			
Ma	nuscript number (if kn	own):ATN	/I-22-3593 <u> </u>		
	•	• • • • • • • • • • • • • • • • • • • •		I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third	e
par to t	ties whose interests m	nay be affected by not necessarily in	the content o	of the manuscript. Disclosure represents a commitmen If you are in doubt about whether to list a	it
	e following questions a nuscript only.	pply to the author	's relationsh	ips/activities/interests as they relate to the current	
to t	_	pertension, you sl	nould declare	defined broadly. For example, if your manuscript pertense all relationships with manufacturers of antihypertense the manuscript.	
	tem #1 below, report a time frame for disclos		•	ed in this manuscript without time limit. For all other i	tems,
		Name all en whom you h relationship none (add r needed)	nave this o or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			ince the initia	al planning of the work	ı
L	All support for the pres manuscript (e.g., fundir				ı
	provision of study				ı
	materials, medical writ article processing charg				ı
	etc.)	503,			ı
	No time limit for this				ı
	item.				ı
		 Tim	ie frame: pas	t 36 months	ı
2	Grants or contracts from		io-maimer pas	t oo months	ı
_	any entity (if not indica				ı
	in item #1 above)				ı

Royalties or licenses

Consulting fees

3

4

_X__None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	_X_None	
0	pending	ANone	
	penunig		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary	_X_None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
	None.		
1			

Da	te:1	.5th, July,2022		
	ur Name:J			
Ma	anuscript Title:	Exploration of new the	rapeutic targets for v	iral hepatic fibrosis, alcoholic hepatic fibrosis, and
no	n-alcoholic hepatic	fibrosis		
Ma	anuscript number (i	f known):ATM-	22-3593	
rel pa to	ated to the content rties whose interest transparency and d	of your manuscript. "R	elated" means any re ne content of the mar cate a bias. If you are	hips/activities/interests listed below that are elation with for-profit or not-for-profit third nuscript. Disclosure represents a commitment e in doubt about whether to list a
	e following question nuscript only.	ns apply to the author's	relationships/activit	ies/interests as they relate to the <u>current</u>
to	the epidemiology o	=	ould declare all relation	roadly. For example, if your manuscript pertains onships with manufacturers of antihypertensive script.
	•	ort all support for the w closure is the past 36 m	•	nanuscript without time limit. For all other items,
		NY 11 .1		10
		Name all enti		ations/Comments
		whom you ha relationship		payments were made to you or to your
		none (add ro		onj
		needed)		
		Time frame: Sin	ce the initial plannin	g of the work
1	All support for the p	oresent _X_None		
-	manuscript (e.g., fu			
	provision of study			
	materials, medical v	writing,		
	article processing c	harges,		
	etc.)			
	No time limit for t	nis		
	item.			
			frame: past 36 mont	ns
2	Grants or contracts			
	any entity (if not in	dicated		

_X_None

X_None

in item #1 above). Royalties or licenses

Consulting fees

3

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	_X_None	
0	pending	ANone	
	penunig		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary	_X_None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
	None.		
1			

Da	te:15th	n, July,2022	
Yo	ur Name:Jun	Xie	
			targets for viral hepatic fibrosis, alcoholic hepatic fibrosis, and
no	n-alcoholic hepatic fibr	rosis	
Ma	anuscript number (if kn	own):ATM-22-3593	
rel pa to	ated to the content of rties whose interests m transparency and does	your manuscript. "Related" nay be affected by the conte	e all relationships/activities/interests listed below that are means any relation with for-profit or not-for-profit third ent of the manuscript. Disclosure represents a commitment bias. If you are in doubt about whether to list a
Th	,.		nships/activities/interests as they relate to the current
to	the epidemiology of hy		be <u>defined broadly</u> . For example, if your manuscript pertains lare all relationships with manufacturers of antihypertensive I in the manuscript.
	item #1 below, report a	all support for the work reposure is the past 36 months.	orted in this manuscript without time limit. For all other items,
	item #1 below, report a	• •	Specifications/Comments (e.g., if payments were made to you or to your
	item #1 below, report a	Name all entities with whom you have this relationship or indications none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
	All support for the pres manuscript (e.g., fundin provision of study materials, medical writ article processing chargetc.)	Name all entities with whom you have this relationship or indica none (add rows as needed) Time frame: Since the integrations,	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the presmanuscript (e.g., funding provision of study materials, medical write article processing chargetc.) No time limit for this	Name all entities with whom you have this relationship or indica none (add rows as needed) Time frame: Since the integrations,	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the pres manuscript (e.g., fundin provision of study materials, medical writ article processing chargetc.)	Name all entities with whom you have this relationship or indica none (add rows as needed) Time frame: Since the integrations,	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the presmanuscript (e.g., funding provision of study materials, medical write article processing chargetc.) No time limit for this	Name all entities with whom you have this relationship or indica none (add rows as needed) Time frame: Since the integration, ges, ges,	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the pres manuscript (e.g., fundin provision of study materials, medical writ article processing chargetc.) No time limit for this item. Grants or contracts from any entity (if not indicate the processing chargets)	Name all entities with whom you have this relationship or indica none (add rows as needed) Time frame: Since the integrations, ges, Time frame:X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) nitial planning of the work
	All support for the pres manuscript (e.g., fundin provision of study materials, medical writ article processing chargetc.) No time limit for this item.	Name all entities with whom you have this relationship or indica none (add rows as needed) Time frame: Since the integrations, ges, Time frame:X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) nitial planning of the work

4

Consulting fees

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	_X_None	
0	pending	ANone	
	penunig		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary	_X_None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
	None.		
1			